Licensing status

Publication and contact information


Fluorescent antibodies to membrane-bound tumor necrosis factor (mTNF) as a predictive biomarker for therapeutic responders

Fluorescent antibodies against mTNF could provide an in vivo molecular diagnostic for predicting response to anti-TNF treatment in Crohn's disease. In patients with Crohn's disease not treated with anti-TNF therapy, live endoscopic imaging of gut mucosa with fluorescently labeled Humira adalimumab, an anti-TNF antibody, identified mTNF-expressing intestinal cells. High numbers of mTNF-expressing cells correlated with clinical response to subsequent anti-TNF antibody therapy, and low numbers of mTNF-expressing cells correlated with lack of clinical response. Next steps include comparable studies in ulcerative colitis and multicenter studies to test a larger population of patients with Crohn's disease.
Humira is marketed by AbbVie Inc. to treat several autoimmune diseases.

SciBX 7(13); doi:10.1038/scibx.2014.388
Published online April 3, 2014

Patent filed by the University of Erlangen-Nuremberg; unavailable for licensing

Atreya, R. et al. Nat. Med.; published online Feb. 23, 2014;
Contact: Markus F. Neurath, University of Erlangen-Nuremberg, Erlangen, Germany